Study title:
Cipro pediatric observational study.interim analysis/ A prospective, open-label, non-randomized, naturalistic, long-term safety surveillance, observational study of either ciprofloxacin (either as oral suspension, oral tablets or sequential IV oral therapy or purely IV therapy) or a non-quinolone antibiotic (either as oral suspension, oral tablets or sequential IV oral therapy or purely IV therapy) in the treatment of pediatric patients with infectious diagnoses.
Type of medicine: Medicines containing chemical active substances
|
Therapeutic area: Bacterial Infections and Mycoses [C01]
|
Brands: Please see report |
MAH holders: Please see report |
Assessment: |
Active substance: CIPROFLOXACIN |
ATC code: |
Document link:
Bayer Pharma_Ciprofloxacin_100225_study_synopsis.pdf
|
Document date: 2011-09-07
|
Study number: BAY-O9867-100225 |
EudraCT number:
|
Scope of study: Clinical |
Population of study subjects:
|
Preterm newborn Infants
|
Newborn infants
(1 to 27 days)
|
Infants and toddlers
(28 days to 24 months)
|
Children
(2 to 11 years)
|
Adolescents
(12 to 18 years)
|
|
-
|
-
|
-
|
Y
|
Y
|